[Topical treatment of glucocorticoid-sensitive dermatoses with diflorasone diacetate].
Treatment with diflorasone diacetate ointment and cream (0.05%) was strikingly successful in a multicenter clinical trial involving 4,651 patients in total suffering from various corticosteroid-sensitive dermatoses. According to the clinical evaluation, 93% of the patients were cured or much improved. Approximately 7% of the patients questioned rated the local tolerance of the two forms of administration as good to very good. Only 4% of the patients rated the tolerance of the ointment or cream as moderate or bad. None of the patients showed any systemic side-effects. The molecular structure of diflorasone-17,21-diacetate and the specific pharmaceutical properties of the ointment and cream evidently guarantee a good bioavailability of the glucocorticosteroid in the skin. Clinical and experimental results confirm that diflorasone diacetate belongs to the group of highly active corticosteroids.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D003872:Dermatitis / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy; D012867:Skin / Q000187:drug effects
D001623:Betamethasone; C014477:diflorasone
Ausserliche Behandlung von Glukokortikoid-empfindlichen Dermatosen mit Diflorason-diacetat.